|1.||Cuzzocrea, Salvatore: 5 articles (10/2011 - 01/2010)|
|2.||Mazzon, Emanuela: 5 articles (10/2011 - 01/2010)|
|3.||Paterniti, Irene: 4 articles (10/2011 - 01/2010)|
|4.||Fujii, Yoshitaka: 4 articles (06/2008 - 06/2003)|
|5.||Esposito, Emanuela: 3 articles (10/2011 - 01/2010)|
|6.||Bramanti, Placido: 3 articles (07/2011 - 01/2010)|
|7.||Impellizzeri, Daniela: 3 articles (07/2011 - 01/2010)|
|8.||Tosaka, Shinya: 3 articles (03/2011 - 01/2007)|
|9.||Cho, Sungsam: 3 articles (03/2011 - 01/2007)|
|10.||Maekawa, Takuji: 3 articles (03/2011 - 01/2007)|
06/01/2003 - "Olprinone is effective for the treatment, but not prevention, of fatigue-induced changes in guinea-pig diaphragmatic contractility."
06/01/2003 - "We therefore examined the efficacy of Olprinone for the treatment and prevention of fatigue-induced changes in guinea-pig diaphragmatic contractility. "
05/01/2006 - "Immediately after the fatigue-producing period, groups 2, 3, and 4 received an initial 10 μg/kg dose of olprinone. "
06/01/2003 - "These results suggest that Olprinone 10(-5)-10(-4) M improves the fatigue-induced changes in guinea-pig diaphragmatic contractility and that pretreatment with Olprinone does not prevent diaphragmatic fatigability. "
06/01/2003 - "Diaphragmatic fatigue was induced by generating rhythmic, repetitive contractions produced by 20-Hz stimulation for 5 min. In the first experiment, after the fatigue-producing period, Olprinone was administered to the organ bath for 5 min. In the second experiment, Olprinone was pretreated for 5 min, and then diaphragmatic fatigue was produced. "
01/01/1989 - "E-1020 did not exacerbate arrhythmias of several experimental models in anesthetized dogs even at high dose of 100 micrograms/kg i.v. These results indicate that E-1020 is an intravenously and orally effective cardiotonic agent with vasodilating property, and that it may be beneficial in the treatment of acute and chronic congestive heart failure."
01/01/2010 - "In clinical settings, olprinone is commonly used to treat congestive cardiac failure, due to its inotropic and vasodilating effects. "
02/01/2009 - "The patient, a female child of 6 months presented signs of cardiac failure and took treatment with olprinone and diuretic. "
01/01/2006 - "Olprinone, a phosphodiesterase (PDE) 3 inhibitor, is used to treat heart failure due to its positive inotropic and vasodilative effects. "
01/01/2003 - "Improvement of cerebral blood flow by olprinone, a phosphodiesterase-3 inhibitor, in mild heart failure."
02/01/2004 - "Although he was in a shock state, olprinone improved the contractility of viable myocardium, increased the cardiac index, and decreased the pulmonary artery pressure. "
07/01/2010 - "In this study, we wanted to evaluate the pharmacological action of olprinone (a PDEIII inhibitor) on SAO shock in mice. "
07/01/2010 - "Our results indicated that olprinone up-regulated cAMP in injured ileum tissue, and decreased the ileum tissue damage after 1 h of reperfusion in SAO shock mice. "
07/01/2010 - "These results could imply a future use of olprinone in the therapy of ischemia and reperfusion shock."
07/01/2011 - "This study provides evidence that olprinone attenuates the degree of zymosan-induced shock in mice."
06/01/2008 - "When hypercapnia was established, the dogs were randomly assigned to 1 of 4 groups: (all dogs were administered a bolus dose of olprinone 10 mg/kg) group 1 was maintained with olprinone 0.1 μg/kg · min(-1); group 2 was maintained with olprinone 0.3 μg/kg · min(-1); group 3 was maintained with olprinone 0.5 μg/kg min(-1); and group 4 received no study drug. "
06/01/2008 - "The purpose of this experimental study was to assess the doserelated effects of olprinone on hypercapnia-induced impairment of diaphragmatic contractility. "
05/01/2007 - "When hypercapnia was established, group 1 received no study drug, group 2 was infused with milrinone (50 g/kg initial dose plus 0.5 g/kg · min(-1) thereafter), and group 3 was infused with olprinone (10 g/kg initial dose plus 0.3 g/kg · min(-1) thereafter). "
06/01/2008 - "Olprinone was associated with a dose-dependent improvement of hypercapnia-induced impairment of diaphragmatic contractility in these pentobarbital-anesthetized dogs."
06/01/2008 - "Dose-related effects of olprinone on hypercapnia-Induced impairment of diaphragmatic contractility in pentobarbital-anesthetized dogs."
|5.||Brain Ischemia (Cerebral Ischemia)
03/01/2010 - "These results suggest that olprinone might be useful for the treatment of patients experiencing global cerebral ischemia."
03/01/2010 - "Our study successfully demonstrated, for the first time, that olprinone had a protective effect on neuronal cells in vitro and in vivo, especially against global cerebral ischemia. "
03/01/2010 - "In a rat model of 10-minute global cerebral ischemia induced by 4-vessel occlusion, 0.3, 3, or 30 microg x kg(-1) x min(-1) olprinone or saline was infused for a periischemic period of 40 minutes (n = 6 for each group). "
03/01/2010 - "We examined whether olprinone directly protected neuronal cells from global cerebral ischemia both in vivo and in vitro. "
03/01/2010 - "The effects of the phosphodiesterase inhibitor olprinone on global cerebral ischemia."
|4.||Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)
|8.||Endothelin-1 (Endothelin 1)